MedPath

Special Drug Use-Results Survey of Parsabiv

Not Applicable
Completed
Conditions
Secondary hyperparathyroidism on hemodidalysis
Registration Number
JPRN-jRCT1080224015
Lead Sponsor
ONO PHARMACEUTICAL CO.,LTD.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
completed
Sex
All
Target Recruitment
1200
Inclusion Criteria

Patients with secondary hyperparathyroidism on hemodialysis for whom Parsabiv is newly administered

Exclusion Criteria

Not provided

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
safety<br>efficacy<br>Safety items : Occurrence of adverse drug reactions/infections, factors considered to influence the safety<br>Efficacy items : Comprehensive improvement, laboratory test values, factors considered to influence the efficacy
Secondary Outcome Measures
NameTimeMethod
other<br>-
© Copyright 2025. All Rights Reserved by MedPath